Clough Capital Partners

Founded -

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 10
Average round size
info
The average size of a deal this fund participated in
$64M
Portfolio companies 9
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 6
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Biopharma
  • Therapeutics
Summary

The main department of described VC is located in the Boston. The company was established in North America in United States.

The common things for fund are deals in the range of 50 - 100 millions dollars. The higher amount of exits for fund were in 2017. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 investment rounds annually. Opposing the other organizations, this Clough Capital Partners works on 54 percentage points more the average amount of lead investments.

The overall number of key employees were 2.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Clough Capital Partners, startups are often financed by Kleiner Perkins, DAG Ventures, OrbiMed. The meaningful sponsors for the fund in investment in the same round are Quan Capital, Qiming Venture Partners, OrbiMed. In the next rounds fund is usually obtained by Novartis.

The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline ARMO BioSciences, Arcellx, Elcelyx Therapeutics Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Therapeutics, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Clough Capital Partners:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
Clough Capital Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Clough Capital Partners:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Arcellx

Biopharma
Health Care
Pharmaceutical
$115M13 Apr 2021 Maryland, United States

Checkmate Pharmaceuticals

Biotechnology
Medical Device
Pharmaceutical
Therapeutics
$85M10 Jun 2020 Cambridge, Massachusetts, United States

Arcellx

Biopharma
Health Care
Pharmaceutical
$85M03 Oct 2019 Maryland, United States

Amphivena Therapeutics

Biotechnology
Health Care
Therapeutics
$62M24 Sep 2019 South San Francisco, California, United States

ARMO BioSciences

Biotechnology
Health Care
Medical Device
$67M29 Aug 2017 Redwood City, California, United States

Apellis Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$60M10 Aug 2017 Massachusetts, United States

Sienna Biopharmaceuticals

Biotechnology
Medical
Pharmaceutical
$40M24 Apr 2017 California, United States

CRISPR Therapeutics

Biopharma
Biotechnology
Genetics
Medical
$38M24 Jun 2016 Cambridge, Massachusetts, United States

Elcelyx Therapeutics

Biotechnology
Health Care
Health Diagnostics
$40M01 Oct 2015 San Diego, California, United States
News
Amunix Raises $117M in Series B Financing

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.

Amunix Pharmaceuticals Receives $117M

– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Clough Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: